Over 50% of GBM patients present a very high rate of epidermal growth factor receptor (EGFR) mutations [5]; in particular, the oncogene epidermal growth factor receptor variant III (EGFRvIII), a constitutively active mutant form of the receptor, is among the most common EGFR mutations in GBM. This evidence concerns the gene EGFR and glioblastoma.